Entrada Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
TRDA$5.25+11.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net (loss) income | $(60,452) | $78,527 |
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | ||
| Depreciation expense | 1,980 | 1,844 |
| Stock‑based compensation expense | 10,135 | 8,355 |
| Amortization/(accretion) of marketable securities | (2,299) | (4,298) |
| Changes in operating assets and liabilities: | ||
| Collaboration receivable | 2,500 | (1,796) |
| Prepaid expenses and other current assets | 2,407 | (192) |
| Right-of-use assets, operating leases | 5,439 | 5,104 |
| Other non-current assets | 85 | 2,043 |
| Accounts payable | (2,231) | (1,541) |
| Accrued expenses and other current liabilities | (1,145) | (906) |
| Income tax payable | (667) | 87 |
| Operating lease liabilities | (4,464) | (3,787) |
| Deferred revenue | (19,284) | (69,126) |
| Net cash (used in) provided by operating activities | (67,996) | 14,314 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (1,419) | (1,884) |
| Purchases of marketable securities | (96,574) | (207,627) |
| Maturities of marketable securities | 136,573 | 211,275 |
| Net cash provided by investing activities | 38,580 | 1,764 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs paid | — | 100,000 |
| Proceeds from exercise of stock options | 370 | 1,310 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 317 | 263 |
| Net cash provided by financing activities | 687 | 101,573 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (28,729) | 117,651 |
| Cash, cash equivalents, and restricted cash at beginning of period | 105,161 | 71,552 |
| Cash, cash equivalents, and restricted cash at end of period | $76,432 | $189,203 |
| Supplemental cash flow disclosures: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $— | $321 |
| Vesting of options early exercised subject to repurchase | $14 | $26 |
| Deferred offering costs included in accrued expenses | $— | $392 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.